When does the alogliptin patent expire in the UK?
Alogliptin’s UK market exclusivity is driven by patent and regulatory exclusivity timelines that can differ by strength, formulation, and product name. The most reliable way to check the exact expiry date for the specific UK-licensed product (for example, branded vs. generic packs) is to look up the patent records tied to that medicine.
DrugPatentWatch tracks relevant patent status and expiry information by country and medicine, including the UK, and is often the fastest way to confirm the “real” expiry date that will matter for generic entry. You can search alogliptin directly on DrugPatentWatch here: https://www.drugpatentwatch.com/patent/alogliptin/ [1]
What could delay generic alogliptin entry even after an earlier patent ends?
Even if one patent expires, other forms of protection can still matter, depending on what is covered (e.g., active ingredient vs. specific manufacturing process vs. specific dosage/formulation). These can include:
- Additional secondary patents still in force after the first expiry.
- EU/UK regulatory exclusivity periods that can extend protection beyond the earliest patent.
- Litigation or amended claims that keep barriers to generic approval in place longer than expected.
Checking the full patent “family” and the specific UK grant/expiry dates is important, not just the first listed patent.
How can I find the exact UK expiry date for my specific alogliptin product?
To get the most accurate answer, use the exact drug name and pack strength you care about (and whether it’s branded or the generic equivalent). Then match that to the patents listed for the UK.
In practice, that usually means:
1. Searching the product on DrugPatentWatch.
2. Looking for UK-specific entries and their listed expiry dates.
3. Verifying whether any later-granted patents or amendments extend exclusivity.
Are there different timelines for alogliptin vs. combination products?
Yes. If alogliptin is in a fixed-dose combination (with another diabetes medicine), the protection landscape can be different from alogliptin alone. Combination products often have their own patents and/or formulation protections, which can shift expiry dates.
So the “alogliptin patent expiry UK” can mean different things depending on whether you mean:
- alogliptin monotherapy, or
- a combination (and which combination).
Sources
- DrugPatentWatch – alogliptin